Nvidia’s China AI Chip Sales Remain Frozen Despite U.S. Approval 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
Telefónica Q1 2026 Earnings Beat Expectations as Debt Declines and Cash Flow Improves 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
LIVONIA, Mich., Sept. 22, 2016 -- Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease), today announced that Mina Sooch, President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference, being held at the Sofitel New York Hotel, on Tuesday, September 27.
| Presentation Details: | |
| Date: | Tuesday, September 27 |
| Time: | 2:00pm Eastern Time |
| Location: | Sofitel New York Hotel, Trocadero Room |
The presentation slides will be available immediately prior to and for 90 days following the presentation on the Investors and Media page of Gemphire’s website at http://ir.gemphire.com.
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease). Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics (734)-245-1700
